Sherlock Sarah P, McCrady Allison, Palmer Jeffrey, Aghamolaey Haleh, Ahlgren André, Widholm Per, Dahlqvist Leinhard Olof, Karlsson Markus
Pfizer Inc, Cambridge, Massachusetts, USA.
Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
Muscle Nerve. 2025 Mar;71(3):343-352. doi: 10.1002/mus.28321. Epub 2024 Dec 23.
INTRODUCTION/AIMS: Improved methodologies to monitor the progression of Duchenne muscular dystrophy (DMD) are needed, especially in the context of clinical trials. We report changes in muscle magnetic resonance imaging (MRI) parameters in participants with DMD, including changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI) and their relationship to changes in functional parameters.
MRI data were obtained as part of a clinical study (NCT02310763) of domagrozumab, an antibody-targeting myostatin that negatively regulates skeletal muscle mass. This post hoc analysis evaluated participants with Dixon MRI data and corresponding functional data at baseline and weeks 49 and 97. Images were analyzed to evaluate changes in adductors, hamstrings, and quadriceps.
There was a positive correlation between increases in LMV and function. LMV changes in adductors (R = 0.51) and quadriceps (R = 0.54) showed a stronger correlation with function than LMV changes in hamstrings (R = 0.30). There was a negative correlation between MFF and MFI, respectively, and function in adductors (R = -0.57, R = -0.42), quadriceps (R = -0.59, R = -0.50), and hamstrings (R = -0.53, R = -048). Participants with preserved North Star Ambulatory Assessment scores had high total LMV (LMV) and low total MFI (MFI). Low ratios of LMV to MFI, or participants with small LMV and high MFI, appeared to have a rapid decline in function and loss of ambulation.
These findings support the use of MRI biomarkers as potential surrogate endpoints in clinical trials of patients with DMD.
ClinicalTrials.gov identifiers: NCT02310763.
引言/目的:需要改进监测杜氏肌营养不良症(DMD)进展的方法,尤其是在临床试验背景下。我们报告了DMD参与者肌肉磁共振成像(MRI)参数的变化,包括瘦肌肉体积(LMV)、肌肉脂肪分数(MFF)和肌肉脂肪浸润(MFI)的变化及其与功能参数变化的关系。
MRI数据是作为一项关于domagrozumab的临床研究(NCT02310763)的一部分获得的,domagrozumab是一种靶向肌肉生长抑制素的抗体,对骨骼肌质量起负调节作用。这项事后分析评估了在基线、第49周和第97周有迪克森MRI数据及相应功能数据的参与者。对图像进行分析以评估内收肌、腘绳肌和股四头肌的变化。
LMV增加与功能之间存在正相关。内收肌(R = 0.51)和股四头肌(R = 0.54)的LMV变化与功能的相关性比腘绳肌的LMV变化(R = 0.30)更强。MFF和MFI分别与内收肌(R = -0.57,R = -0.42)、股四头肌(R = -0.59,R = -0.50)和腘绳肌(R = -0.53,R = -0.48)的功能呈负相关。保留北极星动态评估分数的参与者总LMV高而总MFI低。LMV与MFI的比率低,或LMV小而MFI高的参与者似乎功能迅速下降并丧失行走能力。
这些发现支持将MRI生物标志物用作DMD患者临床试验中潜在的替代终点。试验注册:ClinicalTrials.gov标识符:NCT02310763。